Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil

dc.creatorMoura, Rodrigo Scaliante
dc.creatorPenna, Gerson Oliveira
dc.creatorCardoso, Ludimila Paula Vaz
dc.creatorPontes, Maria Araci de Andrade
dc.creatorCruz, Rossilene
dc.creatorGonçalves, Heitor de Sá
dc.creatorPenna, Maria Lucia Fernandes
dc.creatorStefani, Mariane Martins de Araújo
dc.creatorBührer-Sékula, Samira
dc.date2020-05-19T17:08:43Z
dc.date2020-05-19T17:08:43Z
dc.date2015
dc.date.accessioned2023-09-26T22:44:08Z
dc.date.available2023-09-26T22:44:08Z
dc.identifierMOURA, Rodrigo Scaliante et al. Description of Leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for Leprosy patients in Brazil. American Journal of Tropical Medicine and Hygine, [Bethesda], v. 92, n. 6, p. 1280–1284, 2016.
dc.identifier0002-9637
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/41306
dc.identifier10.4269/ajtmh.14-0049
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8882544
dc.descriptionGerson Oliveira Penna - Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento.
dc.descriptionThe uniform multidrug therapy clinical trial, Brazil (U-MDT/CT-BR), database was used to describe and report the performance of available tools to classify 830 leprosy patients as paucibacillary (PB) and multibacillary (MB) at baseline. In a modified Ridley and Jopling (R&J) classification, considering clinical features, histopathological results of skin biopsies and the slit-skin smear bacterial load results were used as the gold standard method for classification. Anti-phenolic glycolipid-I (PGL-I) serology by ML Flow test, the slit skin smear bacterial load, and the number of skin lesions were evaluated. Considering the R&J classification system as gold standard, ML Flow tests correctly allocated 70% patients in the PB group and 87% in the MB group. The classification based on counting the number of skin lesions correctly allocated 46% PB patients and 99% MB leprosy cases. Slit skin smears properly classified 91% and 97% of PB and MB patients, respectively. Based on U-MDT/CT-BR results, classification of leprosy patients for treatment purposes is unnecessary because it does not impact clinical and laboratories outcomes. In this context, the identification of new biomarkers to detect patients at a higher risk to develop leprosy reactions or relapse remains an important research challenge.
dc.formatapplication/pdf
dc.languageeng
dc.publisherThe American Society of Tropical Medicine and Hygiene
dc.rightsopen access
dc.subjectCross-Sectional Studies
dc.subjectLeprostatic Agents
dc.subjectLeprosy
dc.subjectLeprosy, Multibacillary
dc.subjectLeprosy, Paucibacillary
dc.subjectLeprosy / pathology
dc.subjectLeprosy / drug therapy
dc.subjectLeprosy
dc.subjectMultidrug therapy
dc.subjectMycobacterium leprae
dc.subjectU-MDT/CT-BR
dc.subjectHanseníase
dc.subjectTratamento Farmacológico
dc.subjectMycobacterium leprae
dc.subjectDiagnóstico
dc.titleDescription of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución